Cost-Effectiveness of Population Screening for Alpha-1 Antitrypsin Deficiency: A Decision Analysis

REFERENCES

• Khoury M J, McCabe L L, McCabe E RB. Population screening in the age of genomic medicine. N Engl J Med 2003; 348: 50–58, [CSA]
   PubMed Web of Science ®Google Scholar
• Farrell P M, Kosorok M R, Laxova A, Shen G, Kosaik R E, Bruns W T, Splaingard M, Mischler E H. Nutritional benefits of neonatal screening for cystic fibrosis. Wisconsin Cystic Fibrosis Neonatal Screening Study Group. N Engl J Med 1997; 337: 963–969, [CSA]
   PubMed Web of Science ®Google Scholar
• Sveger T, Thelin T. Four-year-old children with alpha 1-antitrypsin deficiency. Clinical follow-up and parental attitudes towards neonatal screening. Acta Paediatr Scand 1981; 70: 171–177, [CSA]
   PubMed Web of Science ®Google Scholar
• Clayton E W. Ethical, legal, and social implications of genomic medicine. N Engl J Med 2003; 349: 562–569, [CSA]
   PubMed Web of Science ®Google Scholar
• McCabe E R. Clinical genetics: compassion, access, science, and advocacy. Genet Med 2001; 3: 426–429, [CSA]
   PubMed Web of Science ®Google Scholar
• O'Brien M L, Buist N R, Murphey W H. Neonatal screening for alpha1-antitrypsin deficiency. J Pediatr 1978; 92: 1006–1010, [CSA]
   PubMed Web of Science ®Google Scholar
• Sveger T, Mazodier P. Alpha 1-antitrypsin screening of 18-year-old men. Thorax 1979; 34: 397–400, [CSA]
   PubMed Web of Science ®Google Scholar
• Piitulainen E, Sveger T. Effect of environmental and clinical factors on lung function and respiratory symptoms in adolescents with alpha1-antitrypsin deficiency. Acta Paediatr 1998; 87: 1120–1124, [CSA]
   PubMed Web of Science ®Google Scholar
• Sveger T, Thelin T, McNeil T F. Young adults with alpha 1-antitrypsin deficiency identified neonatally: their health, knowledge about and adaptation to the high-risk condition. Acta Paediatr 1997; 86: 37–40, [CSA]
   PubMed Web of Science ®Google Scholar
• Thelin T, McNeil T F, Aspegren-Jansson E, Sveger T. Psychological consequences of neonatal screening for alpha 1-antitrypsin deficiency. Parental reactions to the first news of their infants' deficiency. Acta Paediatr Scand 1985; 74: 787–793, [CSA]
   PubMed Web of Science ®Google Scholar
• Fost N, Farrell P M. A prospective randomized trial of early diagnosis and treatment of cystic fibrosis: a unique ethical dilemma. Clin Res 1989; 37: 495–500, [CSA]
   PubMedGoogle Scholar
• The Alpha-1-Antitrypsin Deficiency Registry Study Group. Survival and FEV1 decline in individuals with severe deficiency of alpha 1-antitrypsin. Am J Respir Crit Care Med 1998; 158: 49–59, [CSA]
   PubMed Web of Science ®Google Scholar
• Seersholm N, Dirksen A, Kok-Jensen A. Airways obstruction and two year survival in patients with severe alpha 1-antitrypsin deficiency. Eur Respir J 1994; 7: 1985–1987, [CSA]
   PubMed Web of Science ®Google Scholar
• Stoller J K. Augmentation therapy for severe alpha 1-antitrypsin deficiency: is the jury still out on a trial?. Thorax 1998; 53: 1007–1009, [CSA]
   PubMed Web of Science ®Google Scholar
• Wall M, Moe E, Eisenberg J, Powers M, Buist N, Buist A S. Long-term follow-up of a cohort of children with alpha-1-antitrypsin deficiency. J Pediatr 1990; 116: 248–251, [CSA]
   PubMed Web of Science ®Google Scholar
• Gildea T R, Shermock K M, Singer M E, Stoller J K. Cost-effectiveness analysis of augmentation therapy for severe alpha1-antitrypsin deficiency. Am J Respir Crit Care Med 2003; 167: 1387–1392, [CSA]
   PubMed Web of Science ®Google Scholar
• American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995; 152: S77–S121, [CSA]
   PubMed Web of Science ®Google Scholar
• McElvaney N G, Stoller J K, Buist A S, Prakash U B, Brantly M L, Schluchter M D, Crystal R G. Baseline characteristics of enrollees in the National Heart, Lung and Blood Institute Registry of alpha 1-antitrypsin deficiency. Alpha 1-Antitrypsin Deficiency Registry Study Group. Chest 1997; 111: 394–403, [CSA]
   PubMed Web of Science ®Google Scholar
• The Alpha 1-Antitrypsin Deficiency Registry Study Group. A registry of patients with severe deficiency of alpha 1-antitrypsin. Design and methods. Chest 1994; 106: 1223–1232, [CSA]
   PubMed Web of Science ®Google Scholar
• CDC. Annual smoking-attributable mortality, years of pitential life lost, and economic costs–United States, 1995–1999. MMWR 2002; 51: 300–303, [CSA]
   PubMedGoogle Scholar
• Brantly M. Personal communication. 2003
   Google Scholar
• Hilleman D E, Dewan N, Malesker M, Friedman M. Pharmacoeconomic evaluation of COPD. Chest 2000; 118: 1278–1285, [CSA]
   PubMed Web of Science ®Google Scholar
• Ramsey S D, Patrick D L, Albert R K, Lewis S, Albert R K, Raghu G. The cost-effectiveness of lung transplantation. A pilot study. University of Washington Medical Center Lung Transplant Study Group. Chest 1995; 108: 1594–1601, [CSA]
   PubMed Web of Science ®Google Scholar
• Sharples L D, Taylor G J, Karnon J, Caine N, Buxton M, McNeil K, Wallwork J. A model for analyzing the cost of the main clinical events after lung transplantation. J Heart Lung Transplant 2001; 20: 474–482, [CSA]
   PubMed Web of Science ®Google Scholar
• Feeny D, Furlong W, Boyle M, Torrance G W. Multi-attribute health status classification systems. Health Utilities Index. Pharmacoeconomics 1995; 7: 490–502, [CSA]
   PubMed Web of Science ®Google Scholar
• Siegel J ES, Weinstein M CP, Russell L BP, Gold M R. Recommendations for reporting cost-effectiveness analyses. JAMA 1996; 276: 1339–1341, October 23/30[CSA]
   PubMed Web of Science ®Google Scholar
• Gold M R, Siegel J E, Russell L B. Cost-effectiveness in health and medicine. Oxford University Press, New York 1996
   Google Scholar
• Silverman E K, Miletich J P, Pierce J A, Sherman L A, Endicott S K, Broze G J, Jr., Campbell E J. Alpha-1-antitrypsin deficiency. High prevalence in the St. Louis area determined by direct population screening. Am Rev Respir Dis 1989; 140: 961–966, [CSA]
   PubMed Web of Science ®Google Scholar
• Anderson R, De Turk P. United States Life Tables, 1999. National Vital Statistics Reports, 2002; 50
   Google Scholar
• Sveger T, Thelin T, McNeil T F. Neonatal alpha 1-antitrypsin screening: parents' views and reactions 20 years after the identification of the deficiency state. Acta Paediatr 1999; 88: 315–318, [CSA]
   PubMed Web of Science ®Google Scholar
• Helton J L, Harmon R J, Robinson N, Accurso F J. Parental attitudes toward newborn screening for cystic fibrosis. Pediatr Pulmonol Suppl 1991; 7: 23–28, [CSA]
   PubMedGoogle Scholar
• McNeil T F, Harty B, Thelin T, Aspegren-Jansson, Sveger T. Identifying children at high somatic risk: long-term effects on mother-child interaction. Acta Psychiatr Scand 1986; 74: 555–562, [CSA]
   PubMed Web of Science ®Google Scholar
• Brantly M L, Mishra V S, Viranovskaya N. Statewide targeted screening and detection of alpha-1 antitrypsin deficient individuals. Am J Respir Crit Care Med 2003; 167: A222, [abstract][CSA]
   Google Scholar